Archives of Virology

, Volume 164, Issue 2, pp 585–593 | Cite as

Baicalein and baicalin as Zika virus inhibitors

  • Adrian Oo
  • Boon Teong Teoh
  • Sing Sin Sam
  • Sazaly Abu Bakar
  • Keivan ZandiEmail author
Brief Report


At present, there is no effective antiviral agent for Zika virus (ZIKV), an arbovirus that is known for its teratogenic effects on newborns. Baicalein and baicalin were found to be capable of downregulating ZIKV replication up to 10 hours postinfection, while prophylactic effects were evident in pre-treated cells. Baicalein exhibited its highest potency during intracellular ZIKV replication, whereas baicalin was most effective against virus entry. Our in silico interaction assays predicted that both compounds exhibited the strongest binding affinities towards ZIKV NS5, while the virus envelope glycoprotein was the least likely target protein. These findings serve as a crucial platform for further in-depth studies to decipher the underlying anti-ZIKV mechanism(s) of each compound.



This work was funded by the University of Malaya via a Postgraduate Research Grant (PPP) (PG151-2016A).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and informed consent

This study does not involve any human participants or animals in any of its experimental procedures.


  1. 1.
    Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D (2017) An update on Zika virus infection. The Lancet 390:2099–2109Google Scholar
  2. 2.
    Heukelbach J, Alencar CH, Kelvin AA, de Oliveira WK, de Góes Cavalcanti LP (2016) Zika virus outbreak in Brazil. J Infect Dev Ctries 10(02):116–120CrossRefGoogle Scholar
  3. 3.
    Méndez N, Oviedo-Pastrana M, Mattar S, Caicedo-Castro I, Arrieta G (2017) Zika virus disease, microcephaly and Guillain-Barré syndrome in Colombia: epidemiological situation during 21 months of the Zika virus outbreak, 2015–2017. Arch Public Health 75(1):65CrossRefGoogle Scholar
  4. 4.
    Chang C, Ortiz K, Ansari A, Gershwin ME (2016) The Zika outbreak of the 21st century. J Autoimmun 68:1–13CrossRefGoogle Scholar
  5. 5.
    Holtzman M, Golden WC, Sheffield JS (2018) Zika virus infection in the pregnant woman. Clin Obstet Gynecol 61(1):177–185Google Scholar
  6. 6.
    de Souza AS, de Oliveira-Szjenfeld PS, de Oliveira Melo AS, de Souza LAM, Batista AGM, Tovar-Moll F (2018) Imaging findings in congenital Zika virus infection syndrome: an update. Child Nerv Syst 34(1):85–93CrossRefGoogle Scholar
  7. 7.
    Gaudry A, Bos S, Viranaicken W, Roche M, Krejbich-Trotot P, Gadea G, Desprès P, El-Kalamouni C (2018) The flavonoid isoquercitrin precludes initiation of Zika virus infection in human cells. Int J Mol Sci 19(4):1093CrossRefGoogle Scholar
  8. 8.
    Mounce BC, Cesaro T, Carrau L, Vallet T, Vignuzzi M (2017) Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding. Antivir Res 142:148–157CrossRefGoogle Scholar
  9. 9.
    Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P (2016) The green tea molecule EGCG inhibits Zika virus entry. Virology 496:215–218CrossRefGoogle Scholar
  10. 10.
    Zandi K, Teoh B-T, Sam S-S, Wong P-F, Mustafa MR, AbuBakar S (2012) Novel antiviral activity of baicalein against dengue virus. BMC Complement Altern Med 12(1):214CrossRefGoogle Scholar
  11. 11.
    Moghaddam E, Teoh B-T, Sam S-S, Lani R, Hassandarvish P, Chik Z, Yueh A, Abubakar S, Zandi K (2014) Baicalin, a metabolite of baicalein with antiviral activity against dengue virus. Sci Rep 4:5452CrossRefGoogle Scholar
  12. 12.
    Oo A, Rausalu K, Merits A, Higgs S, Vanlandingham D, Bakar SA, Zandi K (2018) Deciphering the potential of baicalin as an antiviral agent for Chikungunya virus infection. Antivir Res 150:101–111CrossRefGoogle Scholar
  13. 13.
    Jin J, Chen Y, Wang D, Ma L, Guo M, Zhou C, Dou J (2018) The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity. Arch Pharm Res 41(6):664–676CrossRefGoogle Scholar
  14. 14.
    Oo A, Hassandarvish P, Chin SP, Lee VS, Bakar SA, Zandi K (2016) In silico study on anti-Chikungunya virus activity of hesperetin. PeerJ 4:e2602CrossRefGoogle Scholar
  15. 15.
    Hassandarvish P, Rothan HA, Rezaei S, Yusof R, Abubakar S, Zandi K (2016) In silico study on baicalein and baicalin as inhibitors of dengue virus replication. RSC Adv 6(37):31235–31247CrossRefGoogle Scholar
  16. 16.
    Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS, Geiss BJ (2017) The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antivir Res 137:134–140CrossRefGoogle Scholar
  17. 17.
    Chan JF-W, Chik KK-H, Yuan S, Yip CC-Y, Zhu Z, Tee K-M, Tsang JO-L, Chan CC-S, Poon VK-M, Lu G (2017) Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antivir Res 141:29–37CrossRefGoogle Scholar
  18. 18.
    Johari J, Kianmehr A, Mustafa MR, Abubakar S, Zandi K (2012) Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus. Int J Mol Sci 13(12):16785–16795CrossRefGoogle Scholar
  19. 19.
    Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW, Wang JM (2000) Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun 276(2):534–538CrossRefGoogle Scholar
  20. 20.
    Cheng F, da Silva SR, Huang I-C, Jung JU, Gao S-J (2018) Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22. J Virol 92(4):e02019–02017Google Scholar
  21. 21.
    Fink SL, Vojtech L, Wagoner J, Slivinski NS, Jackson KJ, Wang R, Khadka S, Luthra P, Basler CF, Polyak SJ (2018) The antiviral drug arbidol inhibits Zika virus. Sci Rep 8(1):8989CrossRefGoogle Scholar
  22. 22.
    Wang B, Thurmond S, Hai R, Song J (2018) Structure and function of Zika virus NS5 protein: perspectives for drug design. Cell Mol Life Sci 75(10):1723–1736CrossRefGoogle Scholar
  23. 23.
    Sacramento CQ, De Melo GR, De Freitas CS, Rocha N, Hoelz LVB, Miranda M, Fintelman-Rodrigues N, Marttorelli A, Ferreira AC, Barbosa-Lima G (2017) The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep 7:40920CrossRefGoogle Scholar
  24. 24.
    Goo L, DeMaso CR, Pelc RS, Ledgerwood JE, Graham BS, Kuhn RJ, Pierson TC (2018) The Zika virus envelope protein glycan loop regulates virion antigenicity. Virology 515:191–202CrossRefGoogle Scholar
  25. 25.
    Persaud M, Martinez-Lopez A, Buffone C, Porcelli SA, Diaz-Griffero F (2018) Infection by Zika viruses requires the transmembrane protein AXL, endocytosis and low pH. Virology 518:301–312CrossRefGoogle Scholar
  26. 26.
    Meertens L, Labeau A, Dejarnac O, Cipriani S, Sinigaglia L, Bonnet-Madin L, Le Charpentier T, Hafirassou ML, Zamborlini A, Cao-Lormeau V-M (2017) Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses. Cell Rep 18(2):324–333CrossRefGoogle Scholar
  27. 27.
    Chu M, Xu L, Zhang M-b, Chu Z-y, Wang Y-d (2015) Role of Baicalin in anti-influenza virus A as a potent inducer of IFN-gamma. BioMed research international 2015Google Scholar
  28. 28.
    Li M, Shi A, Pang H, Xue W, Li Y, Cao G, Yan B, Dong F, Li K, Xiao W (2014) Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. J Ethnopharmacol 156:210–215CrossRefGoogle Scholar
  29. 29.
    Fangueiro JF, Calpena AC, Clares B, Andreani T, Egea MA, Veiga FJ, Garcia ML, Silva AM, Souto EB (2016) Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): in vivo, in vitro and ex vivo studies. Int J Pharm 502(1–2):161–169CrossRefGoogle Scholar
  30. 30.
    Pechenov S, Bhattacharjee H, Yin D, Mittal S, Subramony JA (2017) Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Adv Drug Deliv Rev 112:106–122CrossRefGoogle Scholar
  31. 31.
    Liu J, Lv S-S, Fu Z-Y, Hou L-L (2018) Baicalein enhances migration and invasion of extravillous trophoblasts via activation of the NF-κB pathway. Med Sci Monit 24:2983CrossRefGoogle Scholar
  32. 32.
    Wang G, Liang J, L-r Gao, Z-p Si, X-t Zhang, Liang G, Yan Y, Li K, Cheng X, Bao Y (2018) Baicalin administration attenuates hyperglycemia-induced malformation of cardiovascular system. Cell Death Dis 9(2):234CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Adrian Oo
    • 1
  • Boon Teong Teoh
    • 1
  • Sing Sin Sam
    • 1
  • Sazaly Abu Bakar
    • 1
  • Keivan Zandi
    • 1
    • 2
    Email author
  1. 1.Tropical Infectious Disease Research and Education Centre, Department of Medical MicrobiologyUniversity of MalayaKuala LumpurMalaysia
  2. 2.Laboratory of Biochemical Pharmacology, Department of Pediatrics, School of MedicineEmory UniversityAtlantaUSA

Personalised recommendations